Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
If nausea persists, consult your healthcare provider for further evaluation and management
No multi-center RCT
Their combined use could lead to faster and more effective fat loss
.jpg)
SLU-PP-332 and 5-amino-1mq have distinct mechanisms of action
US$ 25.13
US$ 21.06
US$ 29.71
US$ 23.68
US$ 24.77
US$ 27.12
